Title |
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac
|
---|---|
Published in |
Frontiers in oncology, February 2019
|
DOI | 10.3389/fonc.2019.00049 |
Pubmed ID | |
Authors |
Jesús A. Junco, Ranfis Rodríguez, Franklin Fuentes, Idania Baladrón, Maria D. Castro, Lesvia Calzada, Carmen Valenzuela, Eddy Bover, Eulogio Pimentel, Roberto Basulto, Niurka Arteaga, Angel Cid-Arregui, Francisco Sariol, Lourdes González, Liliana Porres-Fong, María Medina, Ayni Rodríguez, A. Hilda Garay, Osvaldo Reyes, Matilde López, Lourdes de Quesada, Allelin Alvarez, Carolina Martínez, Marleny Marrero, Guillermo Molero, Alfredo Guerra, Pedro Rosales, Carlos Capote, Sahily Acosta, Idania Vela, Lina Arzuaga, Ana Campal, Erlán Ruiz, Elier Rubio, Pável Cedeño, María Carmen Sánchez, Pedro Cardoso, Rolando Morán, Yairis Fernández, Magalys Campos, Henio Touduri, Dania Bacardi, Indalecio Feria, Amilcar Ramirez, Karelia Cosme, Pedro López Saura, Maricel Quintana, Verena Muzio, Ricardo Bringas, Marta Ayala, Mario Mendoza, Luis E. Fernández, Adriana Carr, Luis Herrera, Gerardo Guillén |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 33% |
Switzerland | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 4 | 20% |
Student > Bachelor | 2 | 10% |
Researcher | 2 | 10% |
Professor | 2 | 10% |
Lecturer | 1 | 5% |
Other | 2 | 10% |
Unknown | 7 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 6 | 30% |
Biochemistry, Genetics and Molecular Biology | 2 | 10% |
Agricultural and Biological Sciences | 1 | 5% |
Nursing and Health Professions | 1 | 5% |
Immunology and Microbiology | 1 | 5% |
Other | 1 | 5% |
Unknown | 8 | 40% |